Emzor Nigeria Partners with European Investment Bank

Emzor Nigeria, a leading pharmaceutical company, has entered into a financial agreement with the European Investment Bank (EIB) to facilitate the development of the first Active Pharmaceutical Ingredients (APIs) manufacturing facility in Sub-Saharan Africa.

This initiative was unveiled during the EU-Nigeria strategic dialogue held last week and aims to address the pressing issue of malaria, which remains endemic in Africa.

Malaria is a significant public health concern, accounting for approximately 60% of all outpatient visits and 30% of hospital admissions in Nigeria.

With the development of this manufacturing facility, Emzor Nigeria aims to bolster its leadership role in the fight against malaria, not only in Nigeria but across the African continent.

The new facility will contribute to the local production of essential medicines, particularly antimalarial drugs, ensuring a stable supply and reducing dependence on imports.

By enhancing the availability of high-quality pharmaceutical products, Emzor Nigeria’s efforts align with broader regional health initiatives to combat this life-threatening disease.

This strategic partnership with EIB represents a significant step towards self-sufficiency in pharmaceutical production for Nigeria and Sub-Saharan Africa.